Document is current

Article History

Received: 3 February 2021

Accepted: 7 May 2021

First Online: 20 May 2021

Declarations

:

: Y. Tabuchi receives instructor fees from Asahi Kasei Pharma, Astellas Pharma, GlaxoSmithKline, Mitsubishi Tanabe Pharma, and Nippon Shinyaku, and speaker fees from AbbVie, Chugai Pharmaceutical, Eli Lilly, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Shinyaku, and Novartis Pharma. M.H. and H.I. work in a department that received financial support from Nagahama City, Toyooka City, and five pharmaceutical companies (Mitsubishi Tanabe Pharma, Chugai Pharmaceutical, UCB Japan, Ayumi, and Asahi Kasei Pharma). M.H. receives research grants and/or speaker fees from Bristol-Myers, Eisai, Eli Lilly, and Mitsubishi Tanabe Pharma. H.I. receives research grants from Bristol-Myers, Eisai, Mochida, and Taisho. The KURAMA cohort study is supported by a grant from Daiichi-Sankyo. The present study was an investigator-initiated study. These companies played no role in study design, data collection or analysis, writing of the manuscript, or the decision to submit for publication. H.M., R.Y., A.I., M.S., M.I., Y. Tsuji, S.N., H.T,. T.N., A.M., and Y.F. declare no competing financial interests.

: This study was conducted in accordance with the principles set down in the Declaration of Helsinki and was approved by the ethics committee of Kyoto University (R0357). All patients provided written informed consent.